D. Boral Capital says Enlivex Therapeutics (ENLV) debt offering, RAIN token exposure reflects 'strategically negative' shift

March 24, 2026 9:28 AM

D. Boral Capital analyst Jason Kolbert reiterated a Hold rating on Enlivex Therapeutics (NASDAQ: ENLV)The analyst commented, "Enlivex’s latest $21M ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found